SABS

SAB Biotherapeutics, Inc. SABS

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode SABS VRCA PLUR NXTC QTTB ANTX JSPR EVAX ITRM BOLD
6M 120.67 % 38.63 % -12.88 % 89.72 % 95.48 % 3.64 % -63.88 % 147.84 % -61.53 % 22.12 %
YTD 6.47 % 15.36 % -20.32 % 8.52 % -12.17 % -17.99 % -91.18 % 24.46 % -79.19 % -53.48 %
1Y 1.28 % 19.97 % -21.59 % -6.14 % -9.28 % -10.24 % -91.36 % 29.21 % -78.23 % -49.60 %
3Y -51.24 % -70.51 % -55.54 % -30.88 % -87.05 % -88.37 % -67.60 % -93.77 % -61.83 % 12 699 900.00 %
5Y -96.11 % -92.39 % -93.02 % -91.43 % -98.68 % -92.60 % -98.16 % -98.84 % -97.40 % 12 699 900.00 %
10Y -96.11 % -95.37 % -96.22 % -95.52 % -99.10 % -92.60 % -98.11 % -98.84 % -99.80 % 12 699 900.00 %
From the beginning -96.11 % -95.37 % -99.98 % -95.52 % -99.10 % -92.60 % -98.11 % -98.84 % -99.80 % 12 699 900.00 %

Dividend

AN2 Therapeutics, Inc.